Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Booking Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Booking Holdings Inc trades at $174.57 (market cap $140.99B). The key difference: Booking Holdings Inc is far larger — about 31.4× ACADIA Pharmaceuticals Inc.'s market cap, and Booking Holdings Inc pays a 0.88% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BKNG | |
|---|---|---|
Market Cap | $4.49B | $140.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $231.02 |
52-Week Low | $20.06 | $154.13 |
Enterprise Value | $3.69B | $143.91B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Booking Holdings (BKNG) trades at $181.95, down 1.41% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with 2025 revenue of $26.92B and net income margin of 22.23%, though Q2 2026 earnings are pending. Analyst consensus remains strongly positive with 64% buy ratings and a $225 price target, representing 24% upside potential from current levels.
BKNG presents a compelling investment case with robust cash flow generation ($9.4B operating cash flow in 2025) and dominant market position, though risks include high debt levels (64% debt-to-asset ratio) and AI disruption concerns. The stock's current valuation at 23.87 P/E appears reasonable given growth prospects, with upcoming Q2 earnings on August 4 serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
